Recombinant Human Nerve Growth Factor for Pediatric Neurotrophic Keratopathy
- PMID: 35726907
- DOI: 10.1097/ICL.0000000000000912
Recombinant Human Nerve Growth Factor for Pediatric Neurotrophic Keratopathy
Abstract
A 4-year-old boy presented with right neurotrophic corneal ulcer, lagophthalmos, and facial palsy 8 months after neurosurgery for synchronous brain tumors. Initial treatment with topical antibiotics, topical corticosteroids, lubrication, and lateral tarsorrhaphy successfully treated the corneal epithelial defect; however, the cornea continued to demonstrate diffuse epitheliopathy and a dense stromal opacity and remained insensate on Cochet-Bonnet esthesiometry. After a course of topical cenegermin, central corneal sensation normalized, and the corneal epitheliopathy was markedly improved. Two years after the completion of cenegermin, corneal sensation was maintained; there were no recurrences of epithelial defects, and the stromal opacity had markedly improved. In vivo confocal microscopy (IVCM) demonstrated the presence of subbasal corneal innervation. This report highlights the safety and prolonged effects of cenegermin for the treatment of pediatric iatrogenic neurotrophic keratopathy, as evidenced by the clinical course and IVCM.
Copyright © 2022 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Conflict of interest statement
The authors have no funding or conflicts of interest to disclose.
References
-
- Saad S, Abdelmassih Y, Saad R, et al. Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes. Ocul Surf 2020;18:231–236.
-
- Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 2018;125:1332–1343.
-
- Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 2020;127:14–26.
-
- Pedrotti E, Bonetto J, Cozzini T, et al. Cenegermin in pediatric neurotrophic keratopathy. Cornea 2019;38:1450–1452.
-
- Fausto R, Ceccuzzi R, Micheletti E, et al. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops. Medicine (Baltimore) 2020;99:e20816.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
